AVLN Company Profile and Key Details

Average 10-day trading volume of 644.02 thousand shares is significantly above the 3-month average of 332.11 thousand, indicating heightened recent market interest.

Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $80.00 to $51.00. The high target offers 142.64% upside. The low target suggests 54.69% downside. The mean target is $61.33. This offers 86.02% upside. Avalyn Pharma Inc. Common Stock earnings surprise history is a mixed track record. The quarter that ended June 03, 2026, missed forecasts by 265.25%.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $61.33, suggesting 86.02% upside. Our AI forecast model points to short-term strength (7.79% over two weeks), a medium-term rise (326.54% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Avalyn Pharma Inc. Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 7.79%, with price expected at $35.54 by July 06, 2026, within a range of $34.42 to $36.68 3-Month Outlook: Projected rise of 326.54%, reaching $140.63 by September 18, 2026, with a range of $140.54 to $140.72. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by June 22, 2027, within a range of $0.00 to $0.00.

Avalyn Pharma Inc. Common Stock (NASDAQ:AVLN) closed at $32.97 USD, gaining $1.52 (4.83%) from the previous close of $31.45. The stock is currently trading near its 52-week high $24.15 and $33.19. With a market capitalization of about $1.46 billion, Avalyn Pharma Inc. Common Stock is classified as a small-cap and shows lower-than-market volatility (beta ~0.00). Key stats such as the average daily volume over the past year has been around 536.64 thousand shares, in line with its 52-week average. Headquartered in Boston, MA, Avalyn Pharma Inc. Common Stock operates in the Healthcare sector and the Medical - Pharmaceuticals industry. Led by CEO Lyn Baranowski, the company employs approximately 50 people and listed since April 30, 2026. Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase.